Testing my breast cancer.

Created for women, by women.

We envision a future where women sacrifice less and live better with and after breast cancer.

These tests were built on the belief that treating cancer should be about more than just saving a life. As responsible scientists and physicians, we have to worry about what comes after – to preserve as much of a woman’s body as possible by keeping her from the toxicities of unnecessary treatment. Personalized medicine has made this achievable.

Learn about the brilliant mind behind the genesis of MammaPrint, Laura van ‘t Veer.

Womer-Powered Science

Created for women, by women.

We envision a future where women sacrifice less and live better with and after breast cancer.

These tests were built on the belief that treating cancer should be about more than just saving a life. As responsible scientists and physicians, we have to worry about what comes after – to preserve as much of a woman’s body as possible by keeping her from the toxicities of unnecessary treatment. Personalized medicine has made this achievable.

Learn about the brilliant mind behind the genesis of MammaPrint, Laura van ‘t Veer.

Womer-Powered Science

Understanding the behavior of your tumor.

The good news is that we can predict how your tumor will react to treatment by doing the right testing. Genomic tests differ from traditional diagnostic tests in that they examine your biology at the deepest possible level. The results give your doctors a more accurate, comprehensive overview of your tumor’s behavior, so you can make better decisions throughout your journey to recovery.

A Risk-of-Recurrence Test

Looks at 70 cancer-related genes to determine your level of risk for cancer returning.

Why MammaPrint?

The first and only breast cancer recurrence test with U.S. FDA 510(k) clearance for women of all ages.

Enabled for use throughout the European Union.

Offers a clear result (Ultra Low, Low, High, and High 2), whereas other diagnostic tests (like Oncotype DX, which only examines 21 genes) are more ambiguous.

The only recurrence test supported by Level 1A evidence from the MINDACT trial

Covered by most health plans in and outside of the U.S.

A Molecular Subtyping Test

Looks at 80 cancer-related genes to identify specific characteristics that make up your tumor’s subtype.

Why BluePrint?

The only commercially available test in the U.S. that tells us whether you’ll respond well to chemotherapy.

Molecular subtyping looks deep into your DNA to see which genes are misbehaving and why, while traditional subtyping, such as IHC (Immunohistochemistry) or FISH (Fluorescence in situ hybridization), only provides a superficial view.

Classifies your cancer type more accurately than traditional tests and shows how it’s related to the future of your disease.

Completes the unique genomic profile provided by MammaPrint, allowing your doctors to consider hundreds of genes and characteristics before deciding on treatment.

Covered by most health plans in and outside of the U.S.

Inspect more genes. Make better decisions.

Together, MammaPrint and BluePrint provide a genomic profile of more than 150 genes responsible for causing and growing your breast cancer. They allow us to classify the cancer as one of four different subtypes

BluePrint Luminal A – Type

BluePrint Luminal B – Type

BluePrint Basal – Type

BluePrint HER2 – Type

Learn more about subtypes

Each subtype is associated with a different rate of growth and type of response to certain therapies. For example, patients with a Luminal A tumor experienced little to no benefit from chemotherapy in the MINDACT Trial.

Combining this information with clinical factors (like your cancer stage or tumor size), your doctors can help you decide on the most appropriate and effective therapy. You may find out you don’t need radical treatments that often come with life-long side effects or huge price tags.

How to get tested